Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor

被引:870
|
作者
Sadler, J. E.
Budde, U.
Eikenboom, J. C. J.
Favaloro, E. J.
Hill, F. G. H.
Holmberg, L.
Ingerslev, J.
Lee, C. A.
Lillicrap, D.
Mannucci, M.
Mazurier, C.
Meyer, D.
Nichols, W. L.
Nishino, M.
Peake, I. R.
Rodeghiero, F.
Schneppenheim, R.
Ruggeri, Z. M.
Srivastava, A.
Montgomery, R. R.
Federici, A. B.
机构
[1] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA
[2] Lab Assoc Prof Arndt & Partners, Hamburg, Germany
[3] Leiden Univ, Med Ctr, Dept Haematol, Leiden, Netherlands
[4] Westmead Hosp, ICPMR, Westmead, NSW 2145, Australia
[5] Birmingham Childrens Hosp NHS Trust, Dept Haematol, Birmingham, W Midlands, England
[6] Univ Lund Hosp, Dept Pediat, S-22185 Lund, Sweden
[7] Univ Hosp Skejby, Dept Clin Immunol, Aarhus, Denmark
[8] Royal Free Hosp, Haemophilia Ctr, London NW3 2QG, England
[9] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[10] IRCCS Maggiore Policlin Hosp, Angelo Bianchi Bonomi Hemophilia Thrombosis Ctr, Dept Med Specialties, Milan, Italy
[11] Regina Elena Fdn, Milan, Italy
[12] Univ Milan, Milan, Italy
[13] Lab Srancais Fractionnement & Biotechnol, Lille, France
[14] Hop Bicetre, INSERM, U770, Le Kremlin Bicetre, France
[15] Mayo Clin, Div Hematol & Internal Med, Rochester, MN USA
[16] Nara Prefectural Nara Hosp, Dept Pediat, Nara, Japan
[17] San Bortolo Hosp, Dept Haematol, Hemophilia & Thrombosis Ctr, Vicenza, Italy
[18] Univ Med Ctr Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany
[19] Scripps Res Inst, Roon Res Lab Arteriosclerosis & Thrombosis, La Jolla, CA USA
[20] Christian Med Coll & Hosp, Dept Hematol, Vellore, Tamil Nadu, India
[21] Blood Res Inst, Milwaukee, WI USA
关键词
ADAMTS-13; classification; pathophysiology; von Willebrand disease;
D O I
10.1111/j.1538-7836.2006.02146.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
von Willebrand disease (VWD) is a bleeding disorder caused by inherited defects in the concentration, structure, or function of von Willebrand factor (VWF). VWD is classified into three primary categories. Type 1 includes partial quantitative deficiency, type 2 includes qualitative defects, and type 3 includes virtually complete deficiency of VWF. VWD type 2 is divided into four secondary categories. Type 2A includes variants with decreased platelet adhesion caused by selective deficiency of high-molecular-weight VWF multimers. Type 2B includes variants with increased affinity for platelet glycoprotein Ib. Type 2M includes variants with markedly defective platelet adhesion despite a relatively normal size distribution of VWF multimers. Type 2N includes variants with markedly decreased affinity for factor VIII. These six categories of VWD correlate with important clinical features and therapeutic requirements. Some VWF gene mutations, alone or in combination, have complex effects and give rise to mixed VWD phenotypes. Certain VWD types, especially type 1 and type 2A, encompass several pathophysiologic mechanisms that sometimes can be distinguished by appropriate laboratory studies. The clinical significance of this heterogeneity is under investigation, which may support further subdivision of VWD type 1 or type 2A in the future.
引用
收藏
页码:2103 / 2114
页数:12
相关论文
共 50 条
  • [21] Changes in von Willebrand factor level and von Willebrand activity with age in type 1 von Willebrand disease
    Rydz, N.
    Grabell, J.
    Lillicrap, D.
    James, P.
    HAEMOPHILIA, 2012, 18 : 198 - 198
  • [22] Optimizing therapy with factor VIII von Willebrand factor concentrates in von Willebrand disease
    Federici, AB
    Mannucci, PM
    HAEMOPHILIA, 1998, 4 : 7 - 10
  • [23] Pharmacokinetics of von Willebrand factor and factor VIII in canine von Willebrand disease and haemophilia A
    Stokol, T
    Trepanier, L
    Parry, BW
    Finnin, BC
    RESEARCH IN VETERINARY SCIENCE, 1997, 63 (01) : 23 - 27
  • [24] Comparative analysis and classification of von Willebrand factor/factor VIII concentrates:: Impact on treatment of patients with von Willebrand disease
    Budde, Ulrich
    Metzner, Hubert J.
    Mueller, Heinz-Georg
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2006, 32 (06): : 626 - 635
  • [25] Pharmacokinetics of von Willebrand factor (human) in patients with von Willebrand disease (vWD)
    Menache, D
    Aronson, DL
    Kennedy, D
    Montgomery, RR
    THROMBOSIS AND HAEMOSTASIS, 1997, : P2097 - P2097
  • [26] Prophylaxis in von Willebrand disease with von Willebrand factor concentrate and nonfactor therapies
    Kwawegen, Calvin B. van
    Leebeek, Frank W. G.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (08)
  • [27] Assessment of von Willebrand Factor Propeptide Improves the Diagnosis of von Willebrand Disease
    Casonato, Alessandra
    Daidone, Viviana
    Padrini, Roberto
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2011, 37 (05): : 456 - 463
  • [28] Diagnostic Value of Measuring Platelet Von Willebrand Factor in Von Willebrand Disease
    Casonato, Alessandra
    Cattini, Maria Grazia
    Daidone, Viviana
    Pontara, Elena
    Bertomoro, Antonella
    Prandoni, Paolo
    PLOS ONE, 2016, 11 (08):
  • [29] Von Willebrand factor testing ratios in the diagnosis and subtyping of von Willebrand disease
    Smock, Kristi J.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2023, 45 : 23 - 29
  • [30] Evaluation of an Automated von Willebrand Factor Activity Assay in von Willebrand Disease
    Trossaert, Marc
    Ternisien, Catherine
    Lefrancois, Armelle
    Llopis, Laura
    Goudemand, Jenny
    Sigaud, Marianne
    Fouassier, Marc
    Caron, Claudine
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2011, 17 (06) : E25 - E29